Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. LEXX

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Anticipating ‘Best Year Ever’ in 2023

Lexaria Bioscience (NASDAQ: LEXX) started calendar 2022 with optimism, which according to CEO Chris Bunka’s recently published annual letter to shareholders (https://ibn.fm/zu8hP), turned out to well founded. Now, as the company begins calendar 2023, “that optimism is, if anything, even … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a new strategic advisor. The company announced that Julian Gangolli, the former president of GW Pharmaceuticals USA, has joined Lexaria as a strategic advisor. During his time at GW … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter

Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka has released an annual letter to shareholders. The detailed letter talks about company highlights throughout the year, including the fact that, despite challenges such as global supply chain disruptions and threatening inflation, “Lexaria … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled “Transdermal And/Or Dermal Delivery Of Lipophilic Active Agents.” The Canadian patent … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable of delivering certain drug molecules more effectively into the human body than their generic forms. That, CEO Chris Bunka contends (https://ibn.fm/yJIUi), allows for various efficiencies … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures 28th Patent in International Portfolio

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. According to … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals

One of the main concerns associated with marketed drugs is low bioavailability. Bioavailability is the amount of a drug or substance that becomes completely available to the intended biological destination and is a measure of the rate and fraction of … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD (TM) Achieves Superior CBD Blood Absorption Levels in Hypertension Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has demonstrated superior cannabidiol (“CBD”) blood absorption levels from its patented DehydraTECH-CBD(TM) relative to those of published, pharmaceutical-grade CBD industry comparators. The results were … Continue reading

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment